CTIS2022-502697-16-00招募中1 期
SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy - SEER-3
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be male or female of any race, at least 18 years of age at Visit 1, Male subjects must agree to use an adequate method of contraception, Have provided written informed consent, Be able and willing to follow instructions, including participation in all study assessments and visits, At the time of Visit 1, have documentation or observation of a Persistent Epithelial Defect (PED) in one or both eyes, defined as a corneal epithelial defect that has not resolved after 1 week of conventional, treatment using non-preserved ocular lubricants, non-preserved topical ophthalmic antibiotics, oral doxycycline, patching, amniotic membrane, serum tears, and/or therapeutic contact lenses. Note that re-screened subjects who failed conventional treatment needs to go through 1 week of conventional treatment again right before Visit 1, Have stage 2 or 3 neurotrophic keratopathy (Mackie Classification) in at least one eye of which the longest dimension (length or width) of the defect measures a minimum length of 1 mm (study eye) and which is confirmed by the Investigator not to be simply superficial punctate keratitis, at Visit 1, Have evidence of decreased corneal sensitivity =40 mm (average of 3 measurements) within the area of the PED or corneal ulceration and outside of the area of the defect within 3 mm of the central cornea using the Cochet-Bonnet aesthesiometer at Visit 1;, Have BCVA score =75 letter counts in the study eye based on the ETDRS protocol, Have at least one eye (the same eye) satisfy all criteria for 4, 5, 6, 7 above, Female subjects of child-bearing potential must be non-lactating and using and agree to continue using an acceptable method of contraception for at least 4 weeks prior to the first dose of study product and until 12 weeks after last dose, and have a negative urine pregnancy test during screening
排除标准
- •Have any condition that, in the opinion of the Investigator, would interfere with the subject’s ability to complete the study, would interfere with the interpretation of safety or efficacy, or would present an undue risk to the subject. In cases of uncertainty, the Investigator should contact the medical monitor for clarification, Have received Botox® injection to induce blepharoptosis in the study eye within 90 days prior to Visit 1, Have used contact lenses (for therapeutic or refractive correction) in the study eye within 14 days prior to Visit 1, or anticipate use of contact lenses during the study period. Note that consented subjects will be instructed to discontinue use of contact lenses for the study eye throughout the study, Have used OxervateTM in the study eye within the past 2 months, Anticipate use of serum tears in the study eye during the study period. Note that use of preservative free artificial tears for at least two weeks at the time of screening may continue throughout the study at the discretion of the Investigator, Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the Investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, optic neuritis, systemic infection, neoplastic diseases, poorly controlled diabetes), Have used drugs which affect lacrimation or function of the trigeminal nerve (e.g., neuroleptics, antipsychotics and anti-histamine drugs including oral pilocarpine and cevimeline, cholinergics including nasal varenicline, cytotoxic cancer therapy, neuroleptics, and antipsychotics) within 30 days of Visit 1 or anticipate use of these systemic medication throughout the course of the study, Have any autoimmune or chronic inflammatory disease that might have hindered the efficacy of the study treatment or its evaluation, could possibly have interfered with the interpretation of study results, or could have been judged by the Investigator to be incompatible with the study visit schedule or conduct (e.g., psoriasis, systemic lupus erythematosus, giant cell arteritis, polyarteritis nodosa, relapsing polychondritis, scleroderma, Behcet’s disease, reactive arthritis, inflammatory bowel disease, ankylosing spondylitis, Graves' disease), q.Be on topical (Ocular/Nasal) immunosuppressive therapy within 30 days prior to screening or is likely to require this during the course of the study; Note that only Systemic and dermal immunosuppressive therapy (including inhalation) with a stable dose for at least two weeks at the time of Visit 1 is permitted, Have a known allergy and/or sensitivity to the study product or its components, History of drug, medication or alcohol abuse or addiction, Have any clinically significant slit-lamp findings in the study eye at Visit 1 that in the opinion of the Investigator may interfere with the study parameters; Examples include stromal keratitis, numerous punctate keratitis or pterygium, and thin cornea, Have participated in an investigational drug study within 30 days prior to screening. In addition, it is necessary that at least 5 half-lives of the previously administered investigational drug have elapsed by Visit 1. Observational studies are not exclusionary, Have fever, inflammation, or systemic signs of illness suggestive o
研究者
相似试验
进行中（未招募）
3 期
A Clinical Study to Test the Use of Cetilistat tablet in over weight individualsCTRI/2019/11/021919Hetero Labs Limited
进行中（未招募）
1 期
A Phase III clinical trial of MK-4117 in Japanese subjects with perennial allergic rhinitis, which means symptoms are present throughout the year.MedDRA version: 19.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisSystem Organ Class: 100000004855Perennial allergic rhinitisEUCTR2017-000186-76-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.606
已完成
3 期
A study of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops for the treatment of Subjects with Ocular Itching associated with Allergic ConjunctivitisCTRI/2018/09/015810Ajanta Pharma Ltd222
已完成
3 期
A Clinical study to check the effect and safety of Olopatadine Hydrochloride Ophthalmic Solution 0.7% w/v compared with Olopatadine Hydrochloride Ophthalmic Solution 0.2% w/v in patients suffering with ocular itching associated with allergic conjunctivitis.CTRI/2018/05/013693Ajanta Pharma Ltd219
进行中（未招募）
不适用
A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy with Genotropin® in Treatment Naive Children with Growth Failure due to Insufficient Secretion of Endogenous Growth HormoneEUCTR2005-000346-36-FIBioPartners GmbH144